PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$16.56 -0.5  -3.0%

Last Trade - 24/09/21

Small Cap
Market Cap £344.0m
Enterprise Value £289.4m
Revenue £n/a
Position in Universe 3775th / 7172

BUZZ-U.S. STOCKS ON THE MOVE-Bed Bath & Beyond, Boeing, AbbVie, Exelixis

Mon 28th June, 2021 2:13pm
* Eikon search string for individual stock moves:  STXBZ 
    * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
    * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh

The S&P 500 and the Nasdaq were on pace to open near record levels as
tech-related growth stocks edged up, while investors awaited data on the health
of a U.S. labor market recovery and corporate earnings later in the week.  .N 
    At 8:55 a.m. ET, Dow e-minis  1YMc1  were down 0.02% at 34,327. S&P 500
e-minis  ESc1  were up 0.13% at 4,276.75, while Nasdaq 100 e-minis  NQc1  were
up 0.32% at 14,385.5.
 The top three NYSE percentage gainers premarket  .PRPG.NQ :
 ** Nine Energy Service Inc  NINE.N , up 9.6%
 ** Build-A-Bear Workshop Inc  BBW.N , up 7.2%
 ** The Beachbody Company Group LLC BODY.N , up 7.0%
 The top three NYSE percentage losers premarket  .PRPL.NQ :
 ** Banco de Chile  BCH.N , down 7.2%
 ** Nevro Corp  NVRO.N , down 5.9%
 ** Drive Shack Inc  DS.N , down 5.4%
 The top three Nasdaq percentage gainers premarket  .PRPG.O :
 ** Millendo Therapeutics Inc  TPST.O , up 1,239.6%
 ** Torchlight Energy Resources Inc  MMAT.O , up 95.2%
 ** QAD Inc  QADB.O , up 81.3%
 The top three Nasdaq percentage losers premarket  .PRPL.O :
 ** Digital Brands Group Inc  DBGI.O , down 14.9%
 ** Exelixis Inc  EXEL.O , down 12.2%
 ** Greenland Technologies Holding Corp  GTEC.O , down 11.1%
  ** Exelixis  EXEL.O : down 12.2% premarket
 BUZZ-Exelixis falls on disappointing interim data from cancer drug combo study
 ** FAT Brands  FAT.O : up 12.9% premarket
 BUZZ-FAT Brands adds more franchises to its plate, hits record high
 ** RedHill  RDHL.O : up 1.9% premarket
 BUZZ-Rises as COVID-19 drug shows promise in lab study against variants
  ** Anavex  AVXL.O : up 28.9% premarket
 BUZZ-Jumps on as Parkinson's disease drug meets main goal of study urn:newsml:reuters.com:*:nL3N2OA2ZQ
 ** Bed Bath & Beyond  BBBY.O : up 5.7% premarket
 BUZZ-Rises on share upgrade urn:newsml:reuters.com:*:nL3N2OA2YJ
 ** CarMax  KMX.N : up 0.5% premarket
 BUZZ-Brokerages say omni-channel tailwinds to make CarMax an industry leader
 ** Syndax Pharma  SNDX.O : up 7.0% premarket
 BUZZ-Rises on FDA fast-track tag for blood cancer therapy  urn:newsml:reuters.com:*:nL3N2OA2VW
  ** MediciNova  MNOV.O : up 4.1% premarket
 BUZZ-MediciNova to test chlorine gas poisoning antidote on mice; shares up
  ** Boeing Co  BA.N : down 1.4% premarket
 BUZZ-Falls as FAA raises safety concerns on 777X urn:newsml:reuters.com:*:nL3N2OA2UG
 ** AbbVie  ABBV.N : up 0.2% premarket
 BUZZ-AbbVie's arthritis drug woes spell safety warnings for rivals- SVB Leerink
 ** So-Young International Inc  SY.O : down 1.3% premarket
 BUZZ-China's So-Young International Inc up on 791 mln yuan stake deal
 ** PDS Biotech  PDSB.O : up 7.3% premarket
 BUZZ-Cantor starts PDS Biotech with 'overweight' on growth prospects
 ** Paysafe Ltd   PSFE.N : up 4.2% premarket
 BUZZ-Rises as Cowen starts coverage with "outperform" urn:newsml:reuters.com:*:nL3N2OA2QM
 ** IBM  IBM.N : up 0.3% premarket
 BUZZ-Expands 5G deals with Verizon, Telefonica  urn:newsml:reuters.com:*:nL3N2OA2QA
  ** Intellia Therapeutics  NTLA.O : up 54.5% premarket
 BUZZ-Surges on positive interim data from study urn:newsml:reuters.com:*:nL3N2OA2N8
  ** Arbutus Biopharma  ABUS.O : up 13.9% premarket
 BUZZ-Rises on promising data from hepatitis B treatment study  urn:newsml:reuters.com:*:nL3N2OA2KK
  ** Baidu  BIDU.O : up 1.1% premarket
 BUZZ-China's Baidu gains as electric vehicle JV hires ex-Cadillac designer
  ** Microsoft Corp  MSFT.O : up 0.6% premarket
 BUZZ-Microsoft looking for 'next leg of growth' from new product initiatives -
Jefferies  urn:newsml:reuters.com:*:nL3N2OA28U

 (Compiled by Arunima Kumar)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.